Further Information
Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Western Blot: 1-2 ug/ml
Immunohistochemistry (FFPE): 2-4 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the p21 antibody to be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
This mAb recognizes a 21kDa protein, identified as the p21WAF1 tumor suppressor protein. This mAb is highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors. p21WAF1 is a specific inhibitor of cdk s and a tumor suppressor involved in the pathogenesis of a variety of malignancies. The expression of this gene acts as an inhibitor of the cell cycle during G1 phase and is tightly controlled by the tumor suppressor protein p53. Its expression is induced by the wild type, but not mutant, p53 suppressor protein. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma, thyroid carcinoma).
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Human recombinant protein was used as the immunogen for the p21 antibody.
1026
Cyclin-dependent kinase inhibitor 1
CDKN1A
Homo sapiens
Liquid
Protein G affinity chromatography
Cancer,Cell Cycle
Does not react with mouse and rat
P38936
Optimal dilutions for each application to be determined by the researcher